ARHGAP10

Across TCGA pan-cancer cohorts, ARHGAP10 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARHGAP10’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ARHGAP10 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARHGAP10 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LSCC are the cancer types where ARHGAP10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGAP10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.534	<.001	11	view →
COAD	Male	III,IV	−1.076	<.001	9	view →
LSCC	Female	II,III,IV	−0.766	<.001	9	view →
CCRCC	Male	III,IV	−0.186	<.001	6	view →
PDAC	All	All	+0.246	<.001	5	view →
OV	All	All	−0.857	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARHGAP10–HNSC

Open the HNSC breakdown →